Shares have risen by 23% since my initial recommendation and have fallen by 40% since my 2018 post-ASCO update.
I provide a recap of the bullish thesis and recent events.
ME-401 continues to display a promising efficacy and safety profile, and the phase 2 TIDAL study offers an efficient path to market.
Voruciclib looks highly intriguing in addressing an established resistance mechanism to treatment with venetoclax, a drug thought to have $3 billion in peak sales potential.
MEI Pharma is a Buy. One key risk is heavy competition in certain indications being targeted (especially from larger firms with much more in the way of resources).